Research Fellow at the Computer-Aided Drug Design Unit of the BLAVATNIK Center for Drug Discovery (BCDD), Tel Aviv University
Dr. Benny Da’adoosh has joined the BCDD after finishing his Ph.D at HUJI (Pharmacy School) under the supervision of Prof. Amiram Goldblum on developing computational methods for finding substrate-selective inhibitors and discovering novel agonists for the nuclear receptor, in cooperation with Genomics Institute of the Novartis Research.
During his years in BCDD, Dr. Benny Da’adoosh is involved in the computational aspects of drug discovery and design, as well as in guiding medicinal chemists. His work contributed to the raising of grants and peer-reviewed papers.
His expertise is computerization of medicinal chemistry such as small molecules data sets creation and analysis, methods for predicting the interactions between small molecules and proteins such as docking, pharmacophore, etc. Dr. Benny Da’adoosh is familiar with variety of programming languages, including Python, Perl, C++, MATLAB, etc., as well as number of computational tools for chemoinformatics (RDkit, OpenBabel), molecular docking (Schrodinger and BioSolvIT suites), pharmacophore screening (Inte:Ligand suite), molecular dynamics (Gromacs and Desmond), SAR (including QSAR) and others.
Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes. Erlichman N, Baram T, Meshel T, Morein D, Da'adoosh B, Ben-Baruch A. Cancers (Basel). 2022 Feb 18;14(4):1042. doi: 10.3390/cancers14041042
Alleviation of a polyglucosan storage disorder by enhancement of autophagic glycogen catabolism. Kakhlon O, Vaknin H, Mishra K, D'Souza J, Marisat M, Sprecher U, Wald-Altman S, Dukhovny A, Raviv Y, Da'adoosh B, Engel H, Benhamron S, Nitzan K, Sweetat S , Permyakova A, Mordechai A, Akman HO, Rosenmann H, Lossos A, Tam J, Minassian BA, Weil M. EMBO Mol Med. 2021 Sep 6;e14554. doi: 10.15252/emmm.202114554
A novel specific PERK activator reduces toxicity and extends survival in Huntington's disease models. Ganz J, Shacham T, Kramer M, Shenkman M, Eiger H, Weinberg N, Iancovici O, Roy S, Simhaev L, Da'adoosh B, Engel H, Perets N, Barhum Y, Portnoy M, Offen D, Lederkremer GZ. Sci Rep. 2020 Apr 23;10(1):6875. doi: 10.1038/s41598-020-63899-4.
Computational design of substrate selective inhibition. Da'adoosh B, Kaito K, Miyashita K, Sakaguchi M, Goldblum A. PLoS Comput Biol. 2020 Mar 20;16(3):e1007713. doi: 10.1371/journal.pcbi.1007713. eCollection 2020 Mar.
Discovering highly selective and diverse PPAR-delta agonists by ligand based machine learning and structural modeling. Da'adoosh B, Marcus D, Rayan A, King F, Che J, Goldblum A. Sci Rep. 2019 Jan 31;9(1):1106. doi: 10.1038/s41598-019-38508-8.
Indexing molecules for their hERG liability. Rayan A, Falah M, Raiyn J, Da'adoosh B, Kadan S, Zaid H, Goldblum A. Eur J Med Chem. 2013 Jul;65:304-14. doi: 10.1016/j.ejmech.2013.04.059. Epub 2013 May 13.
GOLDBLUM, Amiram; CHE, Jianwei; RAYAN, Anwar; MARCUS, David; DAADOOSH Binyamin. AGONISTS OF PPAR-δ. International Application No PCT/IL2019/051311
Inhibition of TMPRSS2 binding to ACE2. 1st conference of the Tel Aviv University Center for Combatting Pandemics. 30.03.22.